TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 0
Operating Income -57.2M
Net Income -51.7M
EPS (Diluted) $-0.81

Balance Sheet Metrics

Total Assets 610.2M
Total Liabilities 75.2M
Shareholders Equity 535.0M
Debt to Equity 0.14

Cash Flow Metrics

Operating Cash Flow -41.2M
Free Cash Flow -54.6M

Revenue & Profitability Trend

Vera Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i00000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i126.2M78.2M69.0M22.5M45.2M
Selling, General & Administrative i41.0M23.8M21.9M11.9M4.0M
Other Operating Expenses i-----
Total Operating Expenses i167.2M102.0M90.9M34.4M49.2M
Operating Income i-167.2M-102.0M-90.9M-34.4M-49.2M
Operating Margin % i0.0%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i20.7M8.0M1.8M15.0K8.0K
Interest Expense i7.6M3.8M992.0K20.0K166.0K
Other Non-Operating Income1.9M1.8M1.1M1.8M-4.1M
Pre-tax Income i-152.1M-96.0M-89.1M-32.6M-53.4M
Income Tax i1.0K1.0K1.0K1.0K1.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-152.1M-96.0M-89.1M-32.6M-53.4M
Net Margin % i0.0%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-144.4M-92.2M-87.3M-34.2M-50.0M
EPS (Basic) i$-2.75$-2.25$-3.35$-2.43$-13.10
EPS (Diluted) i$-2.75$-2.25$-3.35$-2.43$-13.10
Basic Shares Outstanding i553266804270707226570676134357064076345
Diluted Shares Outstanding i553266804270707226570676134357064076345

Income Statement Trend

Vera Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i92.6M45.7M43.5M79.7M53.7M
Short-term Investments i548.2M115.0M71.2M0-
Accounts Receivable i-----
Inventory i-----
Other Current Assets913.0K3.2M719.0K480.0K392.0K
Total Current Assets i651.2M172.0M125.7M82.5M54.3M
Non-Current Assets
Property, Plant & Equipment i960.0K92.0K51.0K00
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets131.0K482.0K513.0K344.0K293.0K
Total Non-Current Assets i4.5M3.5M5.7M1.2M293.0K
Total Assets i655.7M175.5M131.4M83.7M54.6M
Liabilities
Current Liabilities
Accounts Payable i7.7M11.1M12.0M1.4M909.0K
Short-term Debt i1.5M2.4M2.6M-2.0K
Current Portion of Long-term Debt-----
Other Current Liabilities---377.0K962.0K
Total Current Liabilities i25.4M22.3M25.6M7.7M2.4M
Non-Current Liabilities
Long-term Debt i53.2M51.3M28.6M4.9M0
Deferred Tax Liabilities i-----
Other Non-Current Liabilities---1.3M1.6M
Total Non-Current Liabilities i53.2M51.6M28.9M6.5M141.5M
Total Liabilities i78.5M73.9M54.5M14.2M143.9M
Equity
Common Stock i64.0K44.0K28.0K21.0K0
Retained Earnings i-461.2M-309.1M-213.1M-124.1M-91.4M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i577.2M101.7M76.9M69.6M-89.3M
Key Metrics
Total Debt i54.6M53.7M31.3M4.9M2.0K
Working Capital i625.8M149.7M100.1M74.8M51.9M

Balance Sheet Composition

Vera Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-152.1M-96.0M-89.1M-32.6M-53.4M
Depreciation & Amortization i105.0K-4.1M-846.0K176.0K251.0K
Stock-Based Compensation i20.8M11.5M8.9M3.0M331.0K
Working Capital Changes i-5.5M-3.8M7.9M424.0K148.0K
Operating Cash Flow i-133.9M-90.2M-67.3M-25.0M-36.0M
Investing Activities
Capital Expenditures i-972.0K-63.0K-62.0K0-42.0K
Acquisitions i-----
Investment Purchases i-703.0M-224.9M-148.5M0-
Investment Sales i279.0M185.6M78.0M0-
Investing Cash Flow i-425.0M-39.4M-70.6M-5.0M-42.0K
Financing Activities
Share Repurchases i-13.0K----
Dividends Paid i-----
Debt Issuance i024.7M19.8M4.9M5.6M
Debt Repayment i---0-130.0K
Financing Cash Flow i593.3M132.5M99.8M53.3M85.1M
Free Cash Flow i-135.7M-92.2M-67.7M-23.7M-34.9M
Net Change in Cash i34.4M2.9M-38.0M23.3M49.0M

Cash Flow Trend

Vera Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -8.04
Forward P/E -7.05
Price to Book 2.99
PEG Ratio -0.09

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -54.84%
Return on Assets -30.24%

Financial Health

Current Ratio 17.03
Debt to Equity 16.56
Beta 1.17

Per Share Data

EPS (TTM) $-3.59
Book Value per Share $7.34
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
vera1.4B-8.042.99-54.84%0.00%16.56
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
Cg Oncology 2.0B-18.132.97-12.00%0.00%0.15
Adaptive 2.0B-12.0711.04-57.60%-59.07%121.39
Vericel 1.8B255.215.872.59%2.85%32.74

Financial data is updated regularly. All figures are in the company's reporting currency.